30 related articles for article (PubMed ID: 33308378)
1. X-aptamers targeting Thy-1 membrane glycoprotein in pancreatic ductal adenocarcinoma.
Wang H; Li X; Lai LA; Brentnall TA; Dawson DW; Kelly KA; Chen R; Pan S
Biochimie; 2021 Feb; 181():25-33. PubMed ID: 33242496
[TBL] [Abstract][Full Text] [Related]
2. An Aptamer-Functionalized DNA Circuit to Establish an Artificial Interaction between T Cells and Cancer Cells.
Wang Z; Zhang Y; Wu L; Chen J; Xie S; He J; Zhang Q; Chen H; Chen F; Liu Y; Zhang Y; Zhuo Y; Wen N; Qiu L; Tan W
Angew Chem Int Ed Engl; 2023 Sep; 62(39):e202307656. PubMed ID: 37423897
[TBL] [Abstract][Full Text] [Related]
3. Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect.
Gao T; Mao Z; Li W; Pei R
J Mater Chem B; 2021 Jan; 9(3):746-756. PubMed ID: 33319876
[TBL] [Abstract][Full Text] [Related]
4. Application of aptamer functionalized nanomaterials in targeting therapeutics of typical tumors.
Yin X; He Z; Ge W; Zhao Z
Front Bioeng Biotechnol; 2023; 11():1092901. PubMed ID: 36873354
[TBL] [Abstract][Full Text] [Related]
5. A GD2-aptamer-mediated, self-assembling nanomedicine for targeted multiple treatments in neuroblastoma theranostics.
Zhang L; Wang M; Zhu Z; Chen S; Wu H; Yang Y; Che F; Li Q; Li H
Mol Ther Nucleic Acids; 2021 Dec; 26():732-748. PubMed ID: 34703655
[TBL] [Abstract][Full Text] [Related]
6. Applications of Aptamer-Bound Nanomaterials in Cancer Therapy.
Zhu L; Zhao J; Guo Z; Liu Y; Chen H; Chen Z; He N
Biosensors (Basel); 2021 Sep; 11(9):. PubMed ID: 34562934
[TBL] [Abstract][Full Text] [Related]
7. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
8. Aptamer-SH2 superbinder-based targeted therapy for pancreatic ductal adenocarcinoma.
Liu AD; Zhou J; Bi XY; Hou GQ; Li SS; Chen Q; Xu H; Cao X
Clin Transl Med; 2021 Mar; 11(3):e337. PubMed ID: 33783993
[TBL] [Abstract][Full Text] [Related]
9. DNA Aptamer Selected against Pancreatic Ductal Adenocarcinoma for in vivo Imaging and Clinical Tissue Recognition.
Wu X; Zhao Z; Bai H; Fu T; Yang C; Hu X; Liu Q; Champanhac C; Teng IT; Ye M; Tan W
Theranostics; 2015; 5(9):985-94. PubMed ID: 26155314
[TBL] [Abstract][Full Text] [Related]
10. Targeted Delivery of C/EBPα -saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth In Vivo.
Yoon S; Huang KW; Reebye V; Mintz P; Tien YW; Lai HS; Sætrom P; Reccia I; Swiderski P; Armstrong B; Jozwiak A; Spalding D; Jiao L; Habib N; Rossi JJ
Mol Ther; 2016 Jun; 24(6):1106-1116. PubMed ID: 26983359
[TBL] [Abstract][Full Text] [Related]
11. A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma.
Clawson GA; Abraham T; Pan W; Tang X; Linton SS; McGovern CO; Loc WS; Smith JP; Butler PJ; Kester M; Adair JH; Matters GL
Nucleic Acid Ther; 2017 Feb; 27(1):23-35. PubMed ID: 27754762
[TBL] [Abstract][Full Text] [Related]
12. Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma.
Li Q; Maier SH; Li P; Peterhansl J; Belka C; Mayerle J; Mahajan UM
Radiat Oncol; 2020 Aug; 15(1):189. PubMed ID: 32758252
[TBL] [Abstract][Full Text] [Related]
13. Antitumor Activity of Lipid-DNA Aptamer Modified T Lymphocytes in Carcinoma.
Zhong L; Gan L; Deng Z; Liu X; Peng H; Tang H; Liu X; Fang F; Yao F; Li W; Liu Z; Hou W; Cui C; Zhao Y; Tan W; Shi W; He J
J Biomed Nanotechnol; 2020 Jul; 16(7):1110-1118. PubMed ID: 33308378
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
